

The use of megavoltage radiation to treat juvenile mandibular ossifying fibroma in a horse

Sarah C. Robbins, Mimi Arighi, Gerry Ottewell

An 8-month-old, Thoroughbred filly was presented to the Ontario Veterinary College (OVC) for evaluation of an enlarging mass involving the rostral portion of the mandible. The mass was noted several weeks after there had been a traumatic injury to the jaw. At the time of admission, there was a firm ulcerated mass, $9.5 \times 9 \times 13.5$ cm in size, involving the body of the mandible, extending from the symphysis of the mandible to the interdental space, and into and between the incisors. Radiographs revealed a large, bony, dense mass of homogenous texture and density. A tentative diagnosis of equine juvenile mandibular ossifying fibroma (JMOF) was made based on the clinical and radiographic appearance of the lesion. The mass was surgically debulked with the horse under general anesthesia. Intraoperative radiographs were taken to help evaluate the amount of tumor left to remove. Histological examination of the mass confirmed the clinical and radiographic diagnosis of JMOF. The tissue consisted of variably sized spicules of mature woven bone, lined by a layer of osteoblasts and surrounded by irregular whorls of loosely woven fibrous tissue.

The filly recovered uneventfully from surgery and was discharged. Six months later, she was readmitted to the OVC with a recurrent proliferative mandibular mass, significantly larger than the initial lesion. The mass had recurred within several weeks of the surgery. The mass now involved most of the rostral part of the body of the mandible, as well as both interdental spaces. Due to the poor prognosis for continued surgical debulking and the owner's reluctance to pursue rostral mandibulectomy, radiation therapy was initiated.

The mandible received a total midline dose of 4000 cGy from a ceiling mounted, Cobalt 60 Picker unit with a source surface distance of 80 cm in 10 fractions on a Monday, Wednesday, and Friday schedule over 22 d. The horse was positioned in a portable stock with the head immobilized in a secure position to allow for accurate placement of the radiation beam. The mass was treated with a bilateral parallel opposed pair technique. The radiation portal encompassed the tumor and a margin of normal tissue. The horse was sedated each time with 5 mg detomidine (Dormosedan, SmithKline Beecham, London, Ontario), IV. During the course of treatment, the oral mucosa became red and inflamed. Saliva production increased and became tenacious in nature and a strong

odor developed from the mass. Despite the acute side effects of the radiation, the filly continued to eat, and these side effects lessened in the 4 wk following the final treatment. Serial follow-up radiographs were taken immediately after the radiation treatment, and at 2 and 10 mo. Radiographically, the mass appeared the same size but was less radiodense at 10 mo. Clinical follow-up of the filly revealed progressive decrease in size of the neoplastic mass at 1 y after the radiation therapy. Two years after radiation therapy, the owner reported that the filly was doing well, with no visible external evidence of the JMOF.

Benign proliferative fibro-osseous lesions of the rostral part of the body of the mandible in the horse are a relatively rare neoplasia (1), although several cases have been described (2,3). These productive, rapidly growing, lesions of the rostral part of the mandible have been described variously as ossifying fibroma-osteoma, osteoma, and osteosarcoma (4,2). In a review of the clinical, radiographic, surgical and pathological data of 6 horses, Morse *et al* (1988) felt that this clinicopathological syndrome should be distinctly classified as JMOF.

Ossifying fibromas are seen most commonly in young horses aged 2 mo to 1 y. Historical evaluation of 5 cases of JMOF suggests that trauma may be a predisposing factor; however, the young age observed both in humans and horses suggests a strong developmental connection (2). Ossifying fibromas are characterized histologically by dense fibroblastic stroma with isomorphic mesenchymal cells, along with fibroblasts and osteoblasts (5). The osteoblasts line relatively regular spicules of bone within a moderately vascularized fibro-osseous stroma. Ossifying fibromas can be distinguished from fibrous dysplasias by the lack of osteoclasts lining the bony spicules in fibrous dysplasias (5). The connective tissue cells of osteosarcomas are pleomorphic and have a high mitotic index, which is absent in ossifying fibromas (5). Although the lesion is locally highly invasive, it has not been reported to have metastatic qualities. A tentative clinical diagnosis of JMOF can be made on the basis of history, signalment, clinical findings, and radiographic appearance of the lesion. Histological examination of the lesion will distinguish JMOF from other progressive, proliferative lesions of the mandible.

Surgical excision, radiation therapy, and cryotherapy have been described for the treatment of various types of mandibular neoplasms in the dog and cat (6–9). Surgical excision of the lesion in the horse appears to result in a high rate of recurrence, although rostral mandibulectomy has been successful (3). Rostral mandibulectomy is a relatively simple procedure in the horse, has a good long-term outcome with regards to cosmetics and function, and in one study, resulted in no complications or recurrence of the neoplasm (3). Radiation therapy has not been described in the literature for use in the horse for the sole treatment of JMOF; however 1 horse with

Can Vet J 1996; 37: 683–684

Department of Clinical Studies, Ontario Veterinary College, Guelph, Ontario N1G 2W1 (Robbins, Arighi); Department of Radiation Therapy, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9 (Ottewell).

Address correspondence and reprint requests to: Dr. Sarah C. Robbins, Department of Veterinary Internal Medicine, Western College of Veterinary Medicine, University of Saskatchewan, 52 Campus Drive, Saskatoon, Saskatchewan S7N 5B4.

JMOF has been reported to have received radiation therapy following surgical debulking of the lesion (3).

Radiation therapy uses ionizing radiation to treat neoplasias. The goal is to deliver an adequate dose of radiation to the localized tumor volume, while not exceeding normal tissue tolerance in the surrounding area (10). Evidence indicates that chromosomal DNA is the principal target for radiation-induced lethality (10). Radiation therapy can be delivered through external beam therapy or with brachytherapy (10).

External beam therapy includes X-rays or gamma rays from megavoltage equipment, such as linear accelerators and Cobalt 60 machines (energies of 1.25 MV and higher), or orthovoltage equipment (300 kV and below) (9). The penetration of the beam increases as the energy of the machine increases (10). With Cobalt 60, the 100% maximum dose is achieved at a depth of 0.5 cm, while a 6MV linear accelerator achieves maximum dose at a depth of 1.5 cm. With low energy X-rays of superficial and orthovoltage machines, the maximum dose is deposited on the surface with the percentage depth dose falling off rapidly depending on the kV and HVT (half value thickness) (10). In this case, Cobalt 60 is an appropriate method of radiation therapy, as the bulk of the tumor is close to or involving the surface of the mandible.

In achieving control of a tumor, it is necessary to deliver an adequate dose of radiation to the total tumor volume, while avoiding unacceptable acute or late effects to the normal tissues (12). The ultimate sterilization of a tumor and cell killing is a random process, dependent on a number of factors. Through dose response curves, it has been shown that the deliverance of a total radiation dose in smaller fractions allows a higher total dose to be given to the tumor with fewer complications to normal tissue and, ultimately, greater tumor control (10). The response of a particular tissue to radiation depends on many factors, including repair, reoxygenation and repopulation, and redistribution of cells within the cell cycle (10). In rapidly dividing cells, the results of the radiation may be evident sooner; whereas in slowly dividing cells, the expression of radiation damage will not be evident until cellular reproduction is

attempted. This explains the slow resolution of the tumor mass in this case.

Radiation therapy has been used to treat many cutaneous neoplasms in the horse, including squamous cell carcinoma, fibrous connective tissue tumors, sarcoids, and solitary lymphomas (11,12). Radiation therapy is often combined with surgery, as surgical excision reduces the tumor burden (6); however, the efficacy of adjunct radiation therapy and surgery has not been evaluated in the horse. The 2-year follow-up in this case showed no evidence of recurrence of the mass. The horse returned to the herd to graze normally within weeks after completion of treatment. The radiation procedure was tolerated very well and resulted in a good cosmetic result. Megavoltage radiation should be considered as the sole treatment or as an adjunct to surgery in the management of JMOF.

CVJ

References

1. Keer KM, Alden CL. Equine neoplasia — A 10 year survey. *Proc Annu Meet Am Assoc Vet Lab Diagn* 1974; 183-187.
2. Morse CC, Saik JE, Richardson DW, Fetter AW. Equine juvenile mandibular ossifying fibroma. *Vet Pathol* 1988; 25: 415-421.
3. Richardson DW, Evans LH, Tulleners EP. Rostral mandibulectomy in five horses. *J Am Vet Med Assoc* 1991; 199: 1179-1182.
4. Barber SM, Clark EG, Fretz PB. Fibroblastic tumor of the pre-maxilla in two horses. *J Am Vet Med Assoc* 1983; 182: 700-702.
5. Jubb F, Kennedy PC, Palmer N. *Pathology of Domestic Animals*, 3rd ed. Orlando: Academic Pr, 1985: 980-982.
6. McLeod DA, Thrall DE. The combination of surgery and radiation in the treatment of cancer: A review. *Vet Surg* 1989; 18: 1-6.
7. Thrall DE. Orthovoltage radiotherapy of oral fibrosarcomas in dogs. *J Am Vet Med Assoc* 1981; 179: 159-162.
8. Penwick RC, Nunamaker DM. Rostral mandibulectomy: A treatment of oral neoplasia in the dog and cat. *J Am Anim Hosp Assoc* 1987; 23: 19-25.
9. Banks WC, Roberts R, Morris E, Hussey DH. Radiotherapy techniques in veterinary medicine. *J Am Vet Med Assoc* 1972; 160: 446-451.
10. Withers HR, Peters EJ. Basic principles of radiotherapy: Biologic aspects of radiation. In: Fletcher GH, ed. *Textbook of Radiotherapy*, 3rd ed. Philadelphia: Lea & Febiger, 1990: 105-219.
11. Fraufenfelder HC, Blain WE, Page EH. 222Rn for treatment of pericocular fibrous connective tissue sarcomas in the horse. *J Am Vet Med Assoc* 1980; 180: 310-312.
12. Blackwood L, Dobson JM. Satellite Article: Radiotherapy in the horse. *Equine Vet Educ* 1994; 6: 95-99.

INDEX OF ADVERTISERS INDEX DES ANNONCEURS

Anitech Identification Systems Inc.	666
Avid Canada	671
Caribbean Veterinary Medical Association	646
Ciba Animal Health.....	641
Clark Cages Inc.	699
Coronado Instruments	704
DAHI Animal Health Inc.	IFC
Gallant Custom Laboratories Inc.	703
Hoptech Inc.	703
Ideal Instrument	704
IDEXX Laboratories Inc.	642
Interceptor Equipment Company.....	704
Invisible Fencing Company Inc.	703
Merck Agvet.....	OBC

Palliser Animal Health Laboratories Ltd.	703
Pottruff & Smith Insurance Brokers Inc.	703
Protronics Professional Electronics	704
Sage-London Industries Incorporated.....	703
Schering Plough Animal Health.....	IBC
Software Solutions Plus Inc.	680
Somerville National Leasing	704
The Bank of Nova Scotia	647
The University of the West Indies	702
The Veterinary Pharmacy Inc.	704
Thomson Partners Ltd.	701
University of Saskatchewan	702
Vita-Tech Canada Inc.	703
Wilson, Jack & Grant.....	703

The participation of advertisers in the CVJ is an indication of their commitment to the advancement of veterinary medicine in Canada. We encourage our readers to give their products and services appropriate consideration. — Ed.

Le support des annonceurs démontre leur engagement pour l'avancement de la médecine vétérinaire au Canada. Nous vous encourageons à prendre connaissance de leurs services et produits. — NDLR